Abbott (NYSE:ABT) kicked off the aptly-named ABSORB trial in Japan to compare its "dissolving" vascular scaffold with its metallic drug-eluting stent in patients with coronary artery disease (CAD).
Stents
J&J’s Cordis lands FDA win for next-gen Adroit guiding catheter
Cordis Corp., the stent-making division of Johnson & Johnson (NYSE:JNJ), landed a new U.S. regulatory win for its next-generation Adroit 6F Guiding Catheter, which the company said can handle more sophisticated cases than earlier versions.
Kentucky cardiologist confesses to unnecessary stenting
Kentucky-based cardiologist Dr. Sandesh Rajaram Patil, 51, admitted this week that he lied about a patient’s heart health in order to justify implanting a stent and submitting a claim for federal reimbursement. Patil is the 3rd cardiologist nationwide and the 1st from Kentucky to face federal prosecution for unnecessary cardiac stenting.
Cook Medical lands FDA win for Evolution biliary gastrointestinal stent
Medical device maker Cook Medical won FDA clearance for its Evolution biliary stent, the latest in the company’s line of controlled-release stents designed for use in the gastrointestinal tract.
Like the rest of the Evolution line, the newly cleared biliary stent delivery system includes recapture technology that allows physicians to modify the stent’s placement before full deployment.
OrbusNeich lands CE Mark for Combo dual-therapy stent
OrbusNeich Medical said it got the green light in Europe for its Combo dual-therapy stent, calling it the 1st such device to both promote healthy tissue growth and prevent the stent from being engulfed by tissue growth.
EuroPCR: Elixir touts “excellent” results for its semi-biodegradable DESyne BD stent
Elixir Medical Corporation revealed positive 2-year trial results for its DESyne BD coronary stent system at this month’s EuroPCR conference.
The novolimus-eluting DESyne BD stent features an ultra-thin polymer coating that enables sustained drug release and degrades over 6 to 9 months, leaving behind a bare metal cobalt chromium stent.
EuroPCR: Volcano, Boston Scientific team up for accurate stent placement study
Volcano Corporation (NSDQ:VOLC) and Boston Scientific (NYSE:BSX) announced a new, cosponsored Syntax study to test precision in stent placement.
The companies announced the upcoming study at the EuroPCR annual meeting in Paris, France.
EuroPCR: New data showing reduced mortality in InspireMD’s MGuard stent trial
InspireMD (OTC:NSPR) presented new 6-month follow up data for its MASTER trial showing lower mortality rates in patients treated with its MGuard stent. The company’s findings were presented today at the STEMI symposium of the annual EuroPCR meeting in Paris, France.
The trial measured all-cause mortality for patients treated with the company’s MGuard stents compared to a control group treated with bare metal stents or drug-eluting stents.
Abbott touts CE Mark for “world’s longest” coronary DES
Stentys enrolls 1st patient in U.S. stent trial
Stentys SA (EPA:STNT) hoping a new U.S. clinical trial will help it win pre-market approval for a self-apposing coronary stent.
The Princeton, N.J.- and Paris-based medical device company said it enrolled the 1st patient in its Apposition V trial, under an investigational device exemption from the U.S. watchdog agency.
Biosensors International wins CE Mark for latest line of drug-eluting stents
Biosensors International (PINK:BSNRY) said it won a green light from European regulators for its BioMatrix NeoFlex drug-eluting stent, the latest in its DES line.